Sign in

Private company

Axonics, Inc.

American surgical and medical instruments and apparatus company1

In its 2024 annual report the company says: “We are a global medical technology company that develops and commercializes innovative and minimally invasive products to treat adults with bladder and bowel dysfunction, including: (i) implantable SNM systems to treat urinary urge incontinence (UUI) and urinary urgency frequency (UUF), together referred to as overactive bladder (OAB), as well as fecal incontinence (FI), and non-obstructive urinary retention (UR); and (ii) a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence (SUI).”4 It is headquartered in Irvine, California.1

Last updated Oct 21, 2026.

Overview

  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersIrvine, California1
  • Incorporated inDE2
  • Business address26 Technology Drive, Irvine, Ca 926182
  • Filer categoryLarge accelerated filer2

See how the biggest companies compare on our leaderboards

We are a global medical technology company that develops and commercializes innovative and minimally invasive products to treat adults with bladder and bowel dysfunction, including: (i) implantable SNM systems to treat urinary urge incontinence (UUI) and urinary urgency frequency (UUF), together referred to as overactive bladder (OAB), as well as fecal incontinence (FI), and non-obstructive urinary retention (UR); and (ii) a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence (SUI).4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

74.9%Gross margin5
-7.1%Operating margin5
-1.7%Net margin5
33.9%Revenue growth, 20235
-1.0%Return on equity5
-$5.6MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Cost of revenue25¢$91.8M
  • Research and development10¢$34.9M
  • Other costs65¢$237.0M
  • Income tax1¢$2.7M

Out of $366.4M in revenue.5 The company lost money this year.

Financial statements

Revenue67895$366.4M in 2023+286134% since 2017
0$100.0M$200.0M$300.0M$400.0M2017: $128.0K$128.0K20172018: $707.0K$707.0K2018+452%2019: $13.8M$13.8M2019+1855%2020: $111.5M$111.5M2020+707%2021: $180.3M$180.3M2021+62%2022: $273.7M$273.7M2022+52%2023: $366.4M$366.4M2023+34%
Gross profit67895$274.6M in 2023+2745440% since 2017
0$100.0M$200.0M$300.0M2017: $10.0K$10.0K20172018: $351.0K$351.0K2018+3410%2019: $7.3M$7.3M2019+1988%2020: $67.1M$67.1M2020+815%2021: $115.7M$115.7M2021+72%2022: $197.7M$197.7M2022+71%2023: $274.6M$274.6M2023+39%
Operating income67895-$26.1M in 2023+43% since 2017
-$100.0M-$75.0M-$50.0M-$25.0M02017: -$18.2M-$18.2M20172018: -$32.1M-$32.1M2018+77%2019: -$80.6M-$80.6M2019+151%2020: -$53.8M-$53.8M2020−33%2021: -$71.8M-$71.8M2021+34%2022: -$64.9M-$64.9M2022−10%2023: -$26.1M-$26.1M2023−60%
Net income67895-$6.1M in 2023−66% since 2017
-$100.0M-$75.0M-$50.0M-$25.0M02017: -$18.1M-$18.1M20172018: -$32.5M-$32.5M2018+80%2019: -$79.9M-$79.9M2019+146%2020: -$54.9M-$54.9M2020−31%2021: -$80.1M-$80.1M2021+46%2022: -$59.7M-$59.7M2022−25%2023: -$6.1M-$6.1M2023−90%
Fiscal year2017201820192020202120222023
Revenue$128.0K6$707.0K7$13.8M8$111.5M9$180.3M5$273.7M5$366.4M5
Cost of revenue$118.0K6$356.0K7$6.5M8$44.4M9$64.6M5$76.0M5$91.8M5
Gross profit$10.0K6$351.0K7$7.3M8$67.1M9$115.7M5$197.7M5$274.6M5
Research and development$12.3M6$19.4M7$20.1M8$29.1M9$37.3M5$34.4M5$34.9M5
Operating expenses$187.5M5$262.6M5$300.6M5
Operating income-$18.2M6-$32.1M7-$80.6M8-$53.8M9-$71.8M5-$64.9M5-$26.1M5
Income before tax-$79.3M5-$62.3M5-$8.7M5
Income tax$1.0K6$1.0K7$1.0K8$1.0K9$782.0K5-$2.6M5-$2.7M5
Net income-$18.1M6-$32.5M7-$79.9M8-$54.9M9-$80.1M5-$59.7M5-$6.1M5
Earnings per share-$2.808-$1.489-$1.865-$1.285-$0.125
Earnings per share (diluted)-$2.808-$1.489-$1.865-$1.285-$0.125
Shares (weighted, basic)43.1M shares546.7M shares549.1M shares5
Shares (weighted, diluted)43.1M shares546.7M shares549.1M shares5

Compare Axonics, Inc. with another company

Corporate structure

Axonics, Inc. sits at the top of its group. 6 entities, 4 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Axonics, Inc.

  • VANGUARD GROUP INC Filed SC 13G/A on Axonics, Inc., latest Feb 13, 2024 (4 filings since Feb 9, 2022)
  • FMR LLC Filed SC 13G/A on Axonics, Inc., latest Feb 12, 2024 (5 filings since Feb 9, 2022)
  • BlackRock Filed SC 13G/A on Axonics, Inc., latest Jan 25, 2024 (3 filings since Feb 3, 2022)
  • Gilde Healthcare U.a. Cooperatieve Iv. Filed SC 13G/A on Axonics, Inc., latest Jun 6, 2022
  • Credit Suisse Filed SC 13G/A on Axonics, Inc., latest Feb 14, 2022
  • Axonics, Inc. Irvine, California
    • Axonics Europe, S.A.S. Subsidiary · France
    • Axonics Modulation Technologies Australia Pty Ltd Subsidiary · Australia
    • Axonics Modulation Technologies, U.K. Limited Subsidiary · United Kingdom
    • Axonics Women’s Health Limited Subsidiary · United Kingdom
    • Bulkamid SARL Subsidiary · France

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Axonics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$14.3M9 Dec 31, 2022$12.5M9 Dec 31, 2021+15.0%
Accumulated depreciation$7.5M9 Dec 31, 2022$5.5M9 Dec 31, 2021+35.9%
Property and equipment, net$6.8M9 Dec 31, 2022$6.9M9 Dec 31, 2021−1.7%
Operating-lease assets (leased space)$22.5M5 Dec 31, 2023$6.2M5 Dec 31, 2022+262.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$104.8M5 Dec 31, 2023$238.8M5 Dec 31, 2022−56.1%
Marketable securities, current$240.1M5 Dec 31, 2023$118.4M5 Dec 31, 2022+102.9%
Debt securities available for sale$240.1M5 Dec 31, 2023$118.4M5 Dec 31, 2022+102.9%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$99.4M5 Dec 31, 2023$94.4M5 Dec 31, 2022+5.3%
Intangible assets, net (excluding goodwill)$81.4M5 Dec 31, 2023$86.3M5 Dec 31, 2022−5.7%
Accumulated amortization$26.5M5 Dec 31, 2023$17.4M5 Dec 31, 2022+52.0%

Inventory

ItemLatestA year beforeChange
Inventory, total$79.9M5 Dec 31, 2023$55.8M5 Dec 31, 2022+43.4%
Raw materials$20.5M5 Dec 31, 2023$19.7M5 Dec 31, 2022+4.1%
Work in process$10.5M5 Dec 31, 2023$5.7M5 Dec 31, 2022+84.2%
Finished goods$48.9M5 Dec 31, 2023$30.4M5 Dec 31, 2022+60.9%

Leadership

Who has led Axonics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Raymond W. Cohen2018–2024

President

  1. Danny L. Dearen2023

Chief financial officer

  1. Danny L. Dearen2023
  2. Kari Leigh Keese2023–2024

Chief operating officer

  1. Rinda Sama2018–2024
20202025
Board members and other officers (20)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Axonics Europe, S.A.S. France3
  • Axonics GmbH Germany3
  • Axonics Modulation Technologies Australia Pty Ltd Australia3
  • Axonics Modulation Technologies, U.K. Limited England and Wales3
  • Axonics Women’s Health Limited England and Wales3
  • Bulkamid SARL France3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • Axonics Modulation Technologies, Inc.Mar 31, 2014 to Mar 3, 20212

Timeline

  1. Nov 15, 20248-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights36
  2. Nov 7, 20248-K Results of operations37
  3. Aug 1, 20248-K Results of operations38
  4. Apr 30, 20248-K Results of operations39
  5. Apr 4, 20248-K Other events40
  6. Mar 25, 20248-K Shareholder vote; Other events41
  7. Feb 28, 20248-K Results of operations42
  8. Jan 8, 20248-K Results of operations; Regulation FD disclosure43
  9. Jan 8, 20248-K Entered a material agreement; Executive or director change44
  10. Oct 30, 20238-K Results of operations45
  11. Oct 4, 20238-K Executive or director change46
  12. Aug 21, 20238-K Executive or director change; Regulation FD disclosure47
  13. Oct 30, 2018New chief executive Raymond W. Cohen becomes CEO13

Calendar

When it reported results

  1. Nov 7, 2024Reported quarterly or annual results37
  2. Aug 1, 2024Reported quarterly or annual results38
  3. Apr 30, 2024Reported quarterly or annual results39
  4. Feb 28, 2024Reported quarterly or annual results42
  5. Jan 8, 2024Reported quarterly or annual results43
  6. Oct 30, 2023Reported quarterly or annual results45
  7. Jul 27, 2023Reported quarterly or annual results48
  8. May 1, 2023Reported quarterly or annual results49

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

171 filings to the SEC since October 2021: 4 annual reports, 10 quarterly reports, 28 major events, 88 insider forms, 14 large holders, 27 other. The latest 20:

  1. Nov 25, 202415-12G FORM 15 EDGAR
  2. Nov 20, 2024EFFECT EDGAR
  3. Nov 15, 2024POS AM EDGAR
  4. Nov 15, 2024S-8 POS EDGAR
  5. Nov 15, 2024S-8 POS EDGAR
  6. Nov 15, 20248-K EDGAR
  7. Nov 15, 20244 PRIMARY DOCUMENT EDGAR
  8. Nov 15, 20244 PRIMARY DOCUMENT EDGAR
  9. Nov 15, 20244 PRIMARY DOCUMENT EDGAR
  10. Nov 15, 20244 PRIMARY DOCUMENT EDGAR
  11. Nov 15, 20244 PRIMARY DOCUMENT EDGAR
  12. Nov 15, 20244 PRIMARY DOCUMENT EDGAR
  13. Nov 15, 20244 PRIMARY DOCUMENT EDGAR
  14. Nov 15, 20244 PRIMARY DOCUMENT EDGAR
  15. Nov 15, 20244 PRIMARY DOCUMENT EDGAR
  16. Nov 15, 20244 PRIMARY DOCUMENT EDGAR
  17. Nov 15, 20244 PRIMARY DOCUMENT EDGAR
  18. Nov 15, 20244 PRIMARY DOCUMENT EDGAR
  19. Nov 12, 20244 PRIMARY DOCUMENT EDGAR
  20. Nov 7, 202410-Q EDGAR

The 171 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

61 open-market trades by officers, directors and large owners since October 2021: 0 buys and 61 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Oct 2, 2024Keese Kari LeighChief Financial OfficerSale2,961$69.41$205.5KForm 4
Jan 31, 2024Noblett KarenChief Medical OfficerSale11,288$67.74$764.6KForm 4
Jan 31, 2024Woock JohnEVP, Chief Mktg/Strtgy OfficerSale15,899$67.74$1.1MForm 4
Jan 31, 2024Ford Alfred J JrChief Commercial OfficerSale16,615$67.74$1.1MForm 4
Jan 31, 2024Keese Kari LeighChief Financial OfficerSale3,489$67.74$236.3KForm 4
Jan 31, 2024COHEN RAYMOND WChief Executive OfficerSale35,161$67.74$2.4MForm 4
Jan 8, 2024Noblett KarenChief Medical OfficerSale15,999$69.00$1.1MForm 4
Dec 28, 2023Noblett KarenChief Medical OfficerSale7,051$63.28$446.2KForm 4
Dec 26, 2023Noblett KarenChief Medical OfficerSale949$63.00$59.8KForm 4
Sep 29, 2023Dearen Danny L.President & CFOSale7,675$56.87$436.5KForm 4
Aug 15, 2023Ford Alfred J JrChief Commercial OfficerSale14,769$62.34$920.7KForm 4
Jul 28, 2023Ford Alfred J JrChief Commercial OfficerSale1,500$62.01$93.0KForm 4
May 26, 2023Dearen Danny L.President & CFOSale7,999$49.47$395.7KForm 4
Apr 21, 2023Dearen Danny L.President & CFOSale20,000$60.20$1.2MForm 4
Apr 20, 2023Dearen Danny L.President & CFOSale2,001$60.01$120.1KForm 4
Mar 31, 2023Dearen Danny L.President & CFOSale15,000$55.27$829.1KForm 4
Feb 21, 2023Sama RindaChief Operating OfficerSale23,321$56.31$1.3MForm 4
Feb 1, 2023Sama RindaChief Operating OfficerSale5,075$60.93$309.2KForm 4
Feb 1, 2023Ford Alfred J JrChief Commercial OfficerSale3,705$60.93$225.8KForm 4
Feb 1, 2023Dearen Danny L.President & CFOSale3,246$60.93$197.8KForm 4

All 61 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • VANGUARD GROUP INCSC 13G/A, 4 filings Feb 9, 2022 to Feb 13, 202450
  • FMR LLCSC 13G/A, 5 filings Feb 9, 2022 to Feb 12, 202451
  • BlackRockSC 13G/A, 3 filings Feb 3, 2022 to Jan 25, 202452
  • Gilde Healthcare U.a. Cooperatieve Iv.SC 13G/A, 1 filing Jun 6, 202253
  • Credit SuisseSC 13G/A, 1 filing Feb 14, 202254

SEC filer profile

How Axonics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAxonics, Inc.1
  • CIK0001603756
  • Employer ID (EIN)45-47440831
  • Filer statusLarge accelerated filer1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address26 Technology Drive, Irvine, CA 926181
  • Phone949-396-63221
  • Shares outstanding51,109,154 as of Nov 5, 202411
  • Public float$2.5B as of Jun 30, 202355
  • On EDGAR sinceMar 31, 20141
  • Filings481 in all: 4 (227), 8-K (68), 3 (31), SC 13G/A (23), 10-Q (19), 424B5 (12), SC 13G (12), 4/A (8)1
    All 41 form types

    CORRESP (7), SC 13D/A (7), 10-K (6), DEF 14A (6), 144 (5), UPLOAD (5), 5 (4), D (4), DEFA14A (3), EFFECT (3), SC 13D (3), 10-K/A (2), 3/A (2), S-1/A (2), S-3ASR (2), S-8 (2), S-8 POS (2), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), CERT (1), CT ORDER (1), D/A (1), DEFM14A (1), DEFR14A (1), DRS (1), POS AM (1), PRE 14A (1), PREM14A (1), S-1 (1), S-1MEF (1), S-3 (1)

  • Latest filingsAnnual report (10-K) Feb 29, 2024
    Quarterly report (10-Q) Nov 7, 2024
    Proxy statement (DEF 14A) Jan 8, 2024
    Latest 8-K (8-K) Nov 15, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
    SEC EDGAROther events
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55